Marcio Souza
CEO
Praxis Precision Medicines
Praxis Precision Medicines develops therapies for central nervous system disorders by utilizing genetic insights to address neuronal excitation-inhibition imbalances. The company focuses on delivering effective treatments for both rare and common conditions, aiming to improve patient outcomes through a patient-guided development approach.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$200MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Central nervous system (CNS) disorders, including genetic epilepsies, often stem from imbalances in neuronal excitation and inhibition. Developing effective treatments for these disorders is challenging due to the complexity of the underlying genetic and biological mechanisms. Current therapeutic approaches may not address the root causes of these imbalances, leading to suboptimal patient outcomes.
Solution
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The company leverages insights from human genetics and advanced translational tools to identify and validate therapeutic targets. Praxis employs a patient-guided development strategy, incorporating patient needs and feedback throughout the drug development process. Their approach aims to deliver targeted, high-impact medicines that address the underlying genetic causes of CNS disorders, offering the potential for more effective and personalized treatments.
Target Audience
The primary target audience includes patients with CNS disorders, particularly those with genetic epilepsies and related conditions characterized by neuronal excitation-inhibition imbalances, as well as the physicians who treat them.
Features
- Focus on therapeutic targets identified through human genetics to increase the probability of clinical success.
- Utilization of translational tools to validate targets and product candidates, providing early proof of biology.
- Patient-guided development strategies to ensure treatments align with patient needs.
- Efficient and rigorous clinical development paths to accelerate proof-of-concept in humans.
- Development of therapies for both rare and common CNS conditions.
- Pipeline includes multiple clinical-stage assets and early-stage programs.